India’s first mRNA vaccine against coronavirus – developed by Pune-based Gennova Biopharmaceuticals Ltd (part of Emcure group of companies) – has been found to be safe and it has been given the go-ahead from the Drugs Controller General of India (DCGI) to move into Phase II and III of clinical trials. The vaccine Subject Expert Committee reviewed the interim Phase I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.
- Latest
